As a viable PET agent, an early phase I clinical trial is investigating [18F]-FTC-146 distribution in patients suffering from complex regional pain syndrome (CRPS) and sciatica to determine how S1R expression is altered in chronic pain states in humans (ClinicalTrials.gov, 2016). The gene discussed is TMBIM4; the disease is Sciatica.